(Date:5/10/2008)...mart to avoid devastating vision injuries, group s...) -- Every year in the United States, about 40,000...he American Academy of Ophthalmology (AAO), which ...rts-specific eye protection properly fitted by an ...arbonate materials offer the highest level of impa...
(Date:5/9/2008)...cated for Maintenance Treatment for ADHD, INDIANA...nd Company,(NYSE: LLY ) announced today that the ...as approved Strattera(R) (atomoxetine HCI) for,mai...ity Disorder (ADHD) in,children and adolescents. S...bitor, is the first FDA-approved non-stimulant to ...
(Date:5/9/2008)...wswire/ -- Los Angeles based Operation USA has,dep...e needs of what is now,an estimated 7 million peop...or devastated wide swaths of Myanmar (aka Burma), ... Rangoon) and throughout its vast rice,growing del...per hour and,struck communities living largely in ...
(Date:5/9/2008)...fghanistan Veterans Gather in Virginia to,Envision...anizations,, CHANTILLY, Va., May 9 /PRNewswire...h year and the U.S. death toll climbs above 4,000 ...iverse coalition of military,and veterans service ...elp,bereaved families and wounded veterans. In som...
Breaking Medicine News(10 mins):Health News:Protective Eyewear Key to Sports Safety 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4(Date:5/9/2008)...Newswire/ -- The risk of the two major,prostate di...PH), can be,reduced by changes in lifestyle, such ...nd eating a healthy diet. Alan Kristal, Dr.P.H., a...Fred Hutchinson Cancer Research,Center in Seattle,...not,feel helpless against prostate cancer or BPH.,...
(Date:5/9/2008)...f early pipeline cancer drug candidates, MELBOURN...pia Limited,(ASX: CYT) today announced that it has...velopment collaboration with Cancer Therapeutics C...ly stage drug discovery pipeline,of kinase inhibit...of the,fastest growing segments of the cancer drug...
(Date:5/8/2008)...h Network Completes 13 Phase-I Clinical Trials; ...elopment, EL SEGUNDO, Calif., May 8 /PRNewswire/ ... clinical trial research service business speciali... development for FDA approval,reports it complete...er 34,active trials in late stage drug development...
(Date:5/8/2008)...Globus Medical, Inc., the largest,privately held s...gnized,leader in motion preservation technology, t... SECURE(R)-C Cervical Artificial Disc IDE study. T...mal motion of the spine in,order to alleviate pain...in,the treatment of symptomatic cervical disc dise...
Breaking Medicine Technology:Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3DaVita Clinical Research Completes Record Number of Renal Trials in 2007 2Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Rockwell Medical Technologies Inc Begins Patient Enrollment for its SFP Dose Ranging Study 313 1Rockwell Medical Technologies Inc Begins Patient Enrollment for its SFP Dose Ranging Study 313 2Rockwell Medical Technologies Inc Begins Patient Enrollment for its SFP Dose Ranging Study 313 3Rockwell Medical Technologies Inc Begins Patient Enrollment for its SFP Dose Ranging Study 313 4Clarient to Present at the UBS 2007 Global Life Sciences Conference 1554 1Clarient to Present at the UBS 2007 Global Life Sciences Conference 1554 2Amyris Biotechnologies Announces 2470 Million Series B Round 671 1Amyris Biotechnologies Announces 2470 Million Series B Round 671 2CuraGen Corporation Announces Appointment of Dr Timothy M Shannon as President and Chief Executive Officer 669 1CuraGen Corporation Announces Appointment of Dr Timothy M Shannon as President and Chief Executive Officer 669 2CuraGen Corporation Announces Appointment of Dr Timothy M Shannon as President and Chief Executive Officer 669 3CuraGen Corporation Announces Appointment of Dr Timothy M Shannon as President and Chief Executive Officer 669 4CuraGen Corporation Announces Appointment of Dr Timothy M Shannon as President and Chief Executive Officer 669 5...2 Diabetes Patients -, MONTREAL, March 26 /CNW/ ... announced positive preliminary results from its,...reatment of Type 2,diabetes using the Company,s ...he study demonstrated that PC-DAC(TM):Exendin-4 wa...d once-weekly at each,of the dosing levels teste...
...Data from ECLIPSE, Largest Safety,Program of Intra... 27, 2007 /PRNewswire-FirstCall/ -- Favorable,find...evidipine),compared to current intravenous antihyp...rtension -- a potentially harmful,elevation in blo...ry -- were presented for the first time at a late-...
Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 2Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 5...al instrument for safe, repeatable tissular ablati...face lesions can be treated, including wrinkles an...eat damage and in most cases with the elimination ...mart 2940 Plus incorporates sophisticated pulse-le...
Tri-Active is the result of DEKA s new technology based on the combination of three different methods capable of restoring a normal balance to your skin. This treatment is designed to dramatically re
...th CW intensities of up to 50 W, ideal for dealing...ficient operative theatres. SmartClinic also suppl...e, designed for even the most complicated and deli... laser pulses for delicate surface ablations ensur...
...ution of Smartepil family by DEKA, a high-tech, fa...nsdermic vascular treatments. Thanks to the preset...us allows for carrying out non-invasive vascular t...ife. The system is fitted with a wide range of int...
Medicine Products: